<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2249">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03687710</url>
  </required_header>
  <id_info>
    <org_study_id>1408015423</org_study_id>
    <nct_id>NCT03687710</nct_id>
  </id_info>
  <brief_title>The Comparative Effectiveness Dementia &amp; Alzheimer's Registry</brief_title>
  <acronym>CEDAR</acronym>
  <official_title>The Comparative Effectiveness Dementia &amp; Alzheimer's Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of using clinical precision medicine to develop lifecourse&#xD;
      interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood&#xD;
      biomarkers (including genetics), and cognition will measured longitudinally to assess the&#xD;
      comparative effectiveness of clinical care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Comparative Effectiveness Dementia &amp; Alzheimer's Registry (CEDAR) Project is a&#xD;
      prospective, observational registry of adult patients at-risk for, or with, a diagnosis of&#xD;
      dementia due to Alzheimer's disease (AD) or other neurodegenerative dementias. The purpose of&#xD;
      this study is to develop a research repository, or database, for information collected during&#xD;
      routine medical care of people with normal memory and family history of AD, or with memory&#xD;
      loss or other changes in thinking. The registry will help generate empirical evidence that&#xD;
      improves knowledge and informs care decisions about risk reduction for dementia due to AD,&#xD;
      and about the effectiveness of a clinical precision medicine intervention. Using a life&#xD;
      course approach to comparative effectiveness research will enable investigators to analyze&#xD;
      the effects of evidence-based multidomain interventions on cognition, biomarkers of AD risk,&#xD;
      and calculated AD risk across the pre-dementia spectrum of AD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2015</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 months</measure>
    <time_frame>every 6 months, for 18 months</time_frame>
    <description>Composite Cognitive Battery (including NIH Toolbox Cognition Battery and other pen-and-paper neuropsychological tests).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cognitive Aging Composite (CAC) every 6 months</measure>
    <time_frame>every 6 months, for 18 months</time_frame>
    <description>Composite Cognitive Battery, including neuropsychological tests related to non-pathological (age-related) cognitive decline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of Australian National University - Alzheimer's Disease Risk Score (ANU-ADRI) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Measure longitudinal changes in a validated Alzheimer's risk scale (score range from -13 to 78) where higher scores confer higher risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Baseline on Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Measure longitudinal changes in a validated Alzheimer's risk scale (score range from 0 to 14) where higher scores confer higher risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on American College of Cardiology / American Heart Association Cardiovascular Risk Percentage at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Measure longitudinal changes in a validated cardiovascular risk scale (higher percentage confers higher risk).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on Multi-Ethnic Study of Atherosclerosis (MESA) Risk Percentage at 18 months.</measure>
    <time_frame>18 months</time_frame>
    <description>Measure longitudinal changes in a validated cardiovascular risk scale (higher percentage confers higher risk).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cholesterol Biomarkers at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Change in blood serum levels of cholesterol (total, LDL, HDL) in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Inflammatory Biomarkers at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Change in blood serum levels of hs-CRP, fibrinogen, Cystatin C in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Metabolism Biomarkers at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Change in blood serum levels of HbA1c and HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Homocysteine at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Change in blood serum level of homocysteine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Vitamin D at 18 months</measure>
    <time_frame>18 months</time_frame>
    <description>Change in blood serum level of Vitamin D</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Multidomain precision medicine intervention</intervention_name>
    <description>Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients will be recruited at the Alzheimer's Prevention Clinic, Weill&#xD;
        Cornell Medicine Memory Disorders Program.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  family history of Alzheimer's disease and no cognitive complaints OR subjective&#xD;
             cognitive decline OR preclinical AD OR mild cognitive impairment due to AD or other&#xD;
             conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Mosconi, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline E Carlton, B.A.</last_name>
    <phone>212-746-2105</phone>
    <email>cca4006@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline E Carlton, B.A.</last_name>
      <phone>212-746-2105</phone>
      <email>cca4006@med.cornell.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>October 11, 2022</last_update_submitted>
  <last_update_submitted_qc>October 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

